Skip to main content
ENTA
NASDAQ Life Sciences

Stockholders Approve Significant Increase in Equity Incentive Plan Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$13.41
Mkt Cap
$389.149M
52W Low
$4.09
52W High
$17.15
52W Position info
228% above low
Off High info
22% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

ENTA has more than doubled off its 52-week low of $4.09 on light trading volume (0.4× avg).

Summary

Enanta Pharmaceuticals' stockholders approved an amendment to its 2019 Equity Incentive Plan, increasing the shares reserved for issuance by 1.6 million, which could lead to over 6% potential dilution.


Key Events · Financing and Capital Events · ENTA

  • Equity Incentive Plan Expanded

    Stockholders approved an amendment to the 2019 Equity Incentive Plan, increasing the number of shares reserved for issuance by 1,600,000 shares.

  • Potential Dilution

    This authorization represents a potential dilution of approximately 6.42% based on current outstanding shares, if all newly reserved shares are issued.

  • Routine Annual Meeting Approvals

    Stockholders also re-elected two Class I directors, approved executive compensation on an advisory basis, and ratified PricewaterhouseCoopers LLP as the independent auditor.


Analysis · ENTA · Life Sciences

The approval to add 1.6 million shares to the equity incentive plan is a notable event for Enanta Pharmaceuticals. While essential for attracting and retaining talent in the life sciences sector, this authorization represents a potential dilution of approximately 6.42% for existing shareholders if all shares are eventually issued. Investors should monitor future share issuances under this expanded plan, as it could impact per-share metrics.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ENTA was trading at $13.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $389.1M. The 52-week trading range was $4.09 to $17.15. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENTA - Latest Insights

ENTA
Nov 16, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.41
Real-time Price: $8.99 info
Change: -$1.42 (-14%) info
Market Cap: $253.1M info
ENTA
Nov 16, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.66
Real-time Price: $8.99 info
Change: -$1.67 (-16%) info
Market Cap: $253.1M info
ENTA
Oct 29, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.15
Real-time Price: $8.99 info
Change: -$2.16 (-19%) info
Market Cap: $253.1M info
ENTA
Oct 28, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.99
Real-time Price: $8.99 info
Change: -$3.00 (-25%) info
Market Cap: $253.1M info
ENTA
Aug 12, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $13.52
Real-time Price: $8.99 info
Change: -$4.53 (-34%) info
Market Cap: $253.1M info